NOTIFICATION OF A CHANGE IN BIOHIT OYJ SHARE OWNERSHIP IN ACCORDANCE WITH THE SECURITIES MARKETS ACT, CHAPTER 2, SECTION 10
BIOHIT OYJ STOCK EXCHANGE RELEASE, 24 JUNE 2009 at 3:30 PM
NOTIFICATION OF A CHANGE IN BIOHIT OYJ SHARE OWNERSHIP IN ACCORDANCE WITH THE
SECURITIES MARKETS ACT, CHAPTER 2, SECTION 10
In accordance with the Securities Markets Act, Chapter 2, Section 9, Biohit Oyj
today received notification that the combined share of voting rights conferred
by shares owned by Professor Pentti Sipponen and Patolab Oy - a company in his
control - has fallen to under one twentieth.
In a transaction made on 24 June 2009, ownership of a total of 900,000 Series B
shares held by Pentti Sipponen was transferred to Biocosmos Oy (450,000 shares)
and Interlab Oy (450,000 shares) - two companies under the control of Professor
Osmo Suovaniemi.
In accordance with the Securities Markets Act, Chapter 2, Section 10, Biohit Oyj
is issuing notification that, as a result of the above transaction, the
percentage of shares and votes held by Pentti Sipponen and any companies in his
control are as follows:
--------------------------------------------------------------------------------
| | Number of | % of shares | % of votes |
| | shares | | |
--------------------------------------------------------------------------------
| Pentti Sipponen | | | |
--------------------------------------------------------------------------------
| Series B shares | 0 | 0.00 | 0.00 |
--------------------------------------------------------------------------------
| Patolab Oy | | | |
| (Business ID 0427816-5) | | | |
--------------------------------------------------------------------------------
| Series B shares | 12,300 | 0.10 | 0.01 |
--------------------------------------------------------------------------------
| Total | 12,300 | 0.10 | 0.01 |
--------------------------------------------------------------------------------
Biohit Oyj's share capital consists of a total of 12,937,627 shares (2,975,500
Series A shares and 9,962,127 Series B shares). Series A shares confer twenty
(20) votes and Series B shares confer one (1) vote. In payment of dividends,
however, a dividend of two (2) per cent higher than the nominal value is paid
for Series B shares than is paid for Series A shares.
Biohit Oyj
Osmo Suovaniemi
President and CEO
Further information:
Osmo Suovaniemi, M.D., Ph.D., Professor
President & CEO
Tel: +358-9-773 861
GSM: +358-40-745 5605
Email: osmo.suovaniemi@biohit.com
Distribution:
Helsinki Exchanges
Central storage facility (www.oam.fi)
Press
www.biohit.com
About Biohit Oyj
Biohit Oyj develops, manufactures and markets liquid handling products and
diagnostic test systems for use in research, health care and industrial
laboratories.
Liquid handling products include electronic and mechanical pipettes and
dispensers, and disposable tips, as well as pipette maintenance and calibration
services. Diagnostics business comprises products and analysis systems for
diagnosing, screening and prevention of gastrointestinal diseases, e.g. the
blood-sample based GastroPanel and GastroView, for diagnosing diseases of the
stomach and associated risks, as well as quick tests for the diagnosis of
lactose intolerance, H. pylori infection and fecal occult blood.
Biohit Group employs 370 people in 8 countries. Biohit Oyj is headquartered in
Finland. Subsidiaries are located in France, Germany, the UK, Russia, China,
Japan and the USA. Additionally, Biohit's products are sold by approximately 450
distributors in 70 countries. Biohit's share (BIOBV) is quoted on NASDAQ OMX
Helsinki.
Read more at www.biohit.com